![Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer](https://oncodaily.com/pub/uploads/2024/07/1920_stockphotoofapersonwearingabreastcancerribbon-1-1280x854.jpg)
Jul 16, 2024, 14:12
Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer
Elisabetta Bonzano, Associate Professor at MIUR, shared on X:
“Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
Both CDK4/6 inhibitors effectively modulate key biological pathways in HR+/HER2‑ breast cancer, nuances in their impact, particularly on the HER2‑enriched signature, are dose‑dependent, influenced by the addition of fulvestrant and warrant further investigation.”
Visit the article website.
Source: Elisabetta Bonzano/X
Aug 24, 2024, 08:54
Aug 24, 2024, 07:24
Aug 24, 2024, 06:55
Aug 24, 2024, 06:23